Effects of Zortress® + Tacrolimus vs. Standard Immunosuppression on Progression of Coronary Artery Calcifications and Bone Disease in de Novo Renal Transplant Recipients
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Kentucky
Age
Any age
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
De novo renal transplant recipients (from deceased or living donors) between 18-70 years of age
Willingness to participate in the study and comply with study requirements as evidenced by signed IRB-approved informed consent
You may not be if
Previous solid organ transplant
Known hypersensitivity to any of the study drugs, or their class, or to any of their excipients
Recipients of an investigational drug within 30 days before transplant
Any abnormal physical or laboratory findings of clinical significance which would interfere with conduct of the study
Females of childbearing potential who are planning to become pregnant, who are pregnant and/or lactating, or unwilling to use medically approved means of contraception
Platelet count \<75,000/mm
White blood cell count of \< 2,000/mm³
Hypercholesterolemia (\>400 mg/dL) or hypertriglyceridemia (\>500 mg/dL) despite lipid-lowering therapy
Presence of any clinically significant infection requiring IV antibiotics
Positive serum HCG (women of childbearing potential)
Spot urine protein to creatinine ratio (UPr/Cr ) ≥ 0.5
Any biopsy-confirmed acute rejection since transplant